Organization (Industry)
AB Science (France)
ClinicalTrials.gov lists AB Science (France) as lead sponsor of 45 trials. It has 27 active development programs and 11 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 3 registered with a 2026 start date. The dashed outline is the pace from the 3 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 1.6 trial starts a year over the five years to September, under the 5 a year the method needs.
This page covers AB Science (France): 45 lead-sponsored trials and 2 legal-entity registrations.
Disease areas (37)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Macular Degeneration | 4 |
| Mastocytosis | 4 |
| Multiple Sclerosis | 4 |
| Alzheimer Disease | 3 |
| Amyotrophic Lateral Sclerosis | 3 |
Showing 5 of 37 disease areas.
Trials by start year as sponsor or collaborator (19)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2026 (partial year) | 3 |
| 2024 | 1 |
| 2022 | 3 |
| 2021 | 2 |
| 2020 | 3 |
| 2018 | 1 |
| 2017 | 2 |
| 2016 | 2 |
| 2015 | 2 |
| 2014 | 4 |
Showing 10 of 19 years.
Prediction, not a registry value: median of 36 months from start to primary completion across 5 trials still running at the 2026-10-09 snapshot; registered median of 51 months across 35 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (27)
Shown in this order: max phase, then active trials.
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| Riluzole | Amyotrophic Lateral Sclerosis | Phase 3 | 3 |
| Masitinib | Dementia | Phase 3 | 3 |
| Masitinib | Alzheimer Disease | Phase 3 | 3 |
| Masitinib | Amyotrophic Lateral Sclerosis | Phase 3 | 2 |
| Masitinib 4.5 mg/kg/day | Amyotrophic Lateral Sclerosis | Phase 3 | 1 |
Showing 5 of 27 active programs.
Approved assets (11)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| GEMCITABINE | 3 |
| Riluzole | 3 |
| SUNITINIB | 2 |
| BORTEZOMIB | 1 |
| Dacarbazine | 1 |
Showing 5 of 11 approved assets.
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 67% hit target (n=21) | 19% on time (n=21) |
Journals published in (20)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| Alzheimer's research & therapy | 2 |
| Annals of oncology : official journal of the European Society for Medical Oncology | 2 |
| Lancet (London, England) | 2 |
| Allergy | 1 |
| American journal of hematology | 1 |
Showing 5 of 20 journals.
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 159 | 13 | 2025-12-02 |
Financing and grant events (1)
| Date | Round type | Amount (USD) | Source |
|---|---|---|---|
| 2026-05-04 | Private placement | 2,989,368 | Form d |
FDA inspection record (1)
| Latest classification | Inspections |
|---|---|
| OAI | 3 |
FDA import refusals (1)
| Refused import lines | Latest refusal |
|---|---|
| 3 | 2026-06-30 |
Organization relationships (11)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| Aalto University | Co sponsors trial with | 1 |
| Technische Universität Dresden | Co sponsors trial with | 1 |
| General University Hospital in Prague | Co sponsors trial with | 1 |
| Icometrix (Belgium) | Co sponsors trial with | 1 |
| Roche (Switzerland) | Co sponsors trial with | 1 |
Showing 5 of 11 relationships.
Latest dated events (212)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2026-06-30 | FDA import refusal | FDA enforcement (warning and untitled letters, recalls, inspections, import refusals, debarment) |
| 2026-06 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-05-04 | Private placement | Funding rounds and grants (NIH RePORTER + SEC EDGAR) |
| 2026-04-22 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-01-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
Showing 5 of 212 events.
Biomarker capability evidence (54)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| ALB | Trial sponsor | Named in trial inclusion criteria |
| ALS2 | Trial sponsor | Named in trial inclusion criteria |
| APOH | Trial sponsor | Named in trial inclusion criteria |
| ATP12A | Trial sponsor | Named in trial inclusion criteria |
| ATP12A | Trial sponsor | Named in trial inclusion criteria |
Showing 5 of 54 evidence rows.
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, sec-reported annual financials, fda warning letters, fda untitled letters, fda recalls, manufacturing and distribution sites, climate targets, as filed, workforce and board diversity, as filed, clia clinical laboratory certificates, and biomarkers this organization publishes on.